Company News_Frontera Therapeutics, Inc.

: 【Conference Announcement】Frontera Therapeutics to Present Innovative Achievements at ARVO 2026

Frontera Therapeutics will present multiple latest clinical research achievements at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), a globally authoritative academic event.
2026-03-06

: Highlights of the 5th Next Generation Gene Therapy Vectors Summit: Frontera Therapeutics Achieves Breakthroughs in Payload Innovation

Dr. Zhong-Dong Shi, Vice President of R&D at Frontera Therapeutics, was invited as a keynote speaker to deliver "Engineering Payload to Increase Expression Durability & Lower Dose"
2025-08-13

: FT-017 Gains FDA and CDE Approval, Pioneering Gene Therapy for Hypertrophic Cardiomyopathy

April 27, 2025 — Frontera Therapeutics announced today that its recombinant adeno-associated virus (rAAV) gene therapy, FT-017, has received clinical trial clearance from both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA).
2025-04-28

: Frontera to Present Innovative Gene Therapy Advances at the 2025 ARVO and ASGCT Annual Meetings

Frontera Therapeutics, a global innovator in recombinant AAV (rAAV)-based gene therapy research and manufacturing, continues to drive innovation across ophthalmology, hematology, and cardiovascular disease. In May 2025, Frontera will present its latest research achievements at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
2025-04-22

: Frontera Therapeutics Announces IND Clearance for FT-003 in Diabetic Retinopathy

March 13, 2025 – Frontera Therapeutics announced today that its proprietary recombinant adeno-associated virus (rAAV) gene therapy, FT-003 Injection, has received Investigational New Drug (IND) clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of Diabetic Retinopathy (DR). This marks the third cleared indication for FT-003, following its previous clearances for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
2025-03-13

: Frontera Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of FT-003 for Diabetic Macular Edema (DME)

Boston, MA, November 25, 2024 – Frontera Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its AAV gene therapy product, FT-003 Injection, for a Phase 2 clinical trial targeting Diabetic Macular Edema (DME). This milestone follows the FDA’s prior clearance for FT-003 to conduct a Phase 2 trial for neovascular age-related macular degeneration (nAMD).
2024-12-30

Company News